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Effective vaccines are not available for most viral diseases. This situation may soon change
when the full force of contemporary molecular biology is applied to immunoprophylaxis. In
certain viral diseases, particularly those affecting the respiratory and gastrointestinal tracts,
live attenuated vaccines are needed to confer effective protection. Until now the major obstacle
to success has been genetic instability. It may be possible to construct stable, satisfactorily at-
tenuated mutants by cloning viral DNA or RNA and then subjecting the cloned DNA to en-
zyme surgery to create viable deletion mutations. Modified cloned DNA derived from positive-
strand viral RNA could then be transferred back into its virus by transfection of cells. Conver-
sion of mutant cloned DNA into negative-strand RNA and transfer into its virus will require a
more elaborate type of rescue.
Recent advances in molecular biology, immunology, and peptide synthesis pro-
vide a basis for producing virtually unlimited quantities of purified viral proteins
and small synthetic viral peptides for use in immunoprophylaxis. Success of this ap-
proach will not be limited by technologic constraints but rather by the poor anti-
genicity of purified antigens and synthetic peptides and the need for potent, accept-
able adjuvants not now available. If the problem of poor antigenicity can be solved,
nonreplicating antigens should prove satisfactory for use in prevention of viral
diseases in which systemic spread plays an important role in pathogenesis.
However, I am less sanguine about the prospects for using nonreplicating antigen
vaccines to prevent viral diseases limited primarily to mucosal surfaces. My thoughts
about immunoprophylaxis against viral infections that affect primarily mucosal sur-
faces are heavily influenced by the important role played by local immunity in
resistance to most respiratory and gastrointestinal pathogens. Also, cytotoxic T cells
have recently been shown to play an important role in recovery from influenza virus
infection. Infection of the respiratory or gastrointestinal tract induces systemic
immunoglobulin and cell-mediated immunity as well as local immunity and thus all
phases of host defense are brought into play. In contrast, inactivated antigens are
less effective in stimulating local immunity and cytotoxic T-cell response. For these
reasons efforts to develop attenuated mutants for use in immunization should con-
tinue.
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LIVE ATTENUATED VIRAL VACCINES
The first vaccine used in man contained live vaccinia virus developed by Jenner
almost 200 years ago for the control of smallpox. During the ensuing two centuries,
vaccinia virus has had a noble record of success in controlling this disease in many
parts of the world. Vaccinia virus also played an essential role in the final eradica-
tion of smallpox.
It is ironic that the origin of this most influential of vaccine virus strains remains
obscure. Attempts to determine the origin of vaccinia using modern molecular
biologic techniques have yielded equivocal results. Vaccinia virus is not identical to
either variola virus or cowpox virus, but has features of both, suggesting that it may
be a recombinant virus [1].
Subsequent live attenuated viral vaccines have had a clearer lineage than vaccinia
virus. Thus, each of the later vaccine viruses was derived from a wild-type human
virus that was passaged serially in an unnatural host leading to the emergence of a
host range mutant that was partially restricted in its growth in man. In this manner,
monkey kidney cell culture was used to derive attenuated mutants ofthepolioviruses
and rubella virus. Attenuated strains of yellow fever virus and measles virus were
derived in the same way, using chick embryo cell culture. Finally, attenuated mumps
virus was selected following serial cultivation in embryonated hens' eggs. In the case
of measles virus, satisfactory attenuation required additional mutations that were
selected for during growth at suboptimal temperature.
Attenuated host range mutants probably accumulate many mutations, making it
difficult to define in a precise way the genetic basis of satisfactory attenuation. For
example, the type 1 poliovirus vaccine strain is estimated to have undergone 35 base
changes during its passage and plaque purification in monkey kidney cell culture [2].
In some instances mutant phenotypes (laboratory markers) that correlate with at-
tenuation have been identified, but their actual role in attenuation has not been
established. Thus, the genetic basis of attenuation of live vaccine viruses now in use
is not known. This is illustrated by the failure of Theiler and associates to produce
additional attenuated mutants of yellow fever virus using the protocol that yielded
the satisfactorily attenuated 17D strain of virus [3].
It should be noted that live viral vaccines are not without their problems. The
most serious of these difficulties is genetic instability that is typified by the emer-
gence of virus with altered phenotype during the course of infection with vaccine
virus. For example, virus with increased neurovirulence for monkeys is often shed
by vaccinees infected with live attenuated poliovirus vaccine [4]. Genetic instability
was also a problem with the live yellow fever virus vaccine during its early history
when some batches of vaccine caused encephalitis [5]. It has been particularly dif-
ficult to address these problems without knowledge of the genetic basis of attenua-
tion.
NEW APPROACHES TO CONSTRUCTION OF ATTENUATED VIRUSES
Influenza
Viruses bearing specific, identifiable, attenuating mutations represent the live vac-
cine strains of the future because the genetic basis for attenuation is known and can
be monitored directly during all phases of vaccine development, manufacture, and
utilization in humans. The greatest success in producing and characterizing such at-
tenuating mutations has been achieved with influenza A virus, whose segmented
genome facilitates the segregation and characterization of individual genes.
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Several groups have sought to produce mutant influenza genes that would confer
a satisfactory level of attenuation upon any virus into which they were transferred
by genetic reassortment. In studies performed by Murphy and associates, chemical
mutagenesis was used to produce temperature-sensitive (ts) mutations on genes that
code for nonsurface viral proteins so that the mutant genes could be transferred into
reassortant viruses bearing the surfaceantigens ofnewepidemic orpandemic strains [6].
It is implicit in this approach that chemically induced ts mutations are primarily
responsible for the attenuation of reassortant viruses bearing ts genes. This was
shown to be the case for reassortants derived from two different tsdonor viruses [6].
Although the ts genes from one of these donor viruses, ts-1A2, conferred a satis-
factory level of attenuation upon a series of reassortant viruses, it became clear that
genetic instability represented an insoluble problem. During infection of a suscepti-
ble child, one of the ts-1A2 reassortants underwent a complex set of genetic altera-
tions, including suppression, that led to loss of the ts phenotype and restoration of
virulence, even though the ts reassortant was greatly restricted in its ability to
replicate in vivo. Genetic instability has also plagued the development of ts mutants
of RS virus suitable for use in immunoprophylaxis.
Another technique now being actively pursued for rapid attenuation of new influ-
enza A viruses involves the use of a donor virus that grows well at a suboptimal tem-
perature that does not support efficient replication of wild-type virus. The A/Ann
Arbor/6/60 (H2N2) donor strain was adapted by Maassab to grow well at 25°C by
serial passage at successively lower temperatures (33°C-25°C) in primary chick
kidney cell culture [7]. This virus was also shown to be tswith a shutofftemperature
for plaque formation of 38°C. Genes from this cold-adapted (ca) donor strain were
transferred to a succession of new antigenic variants of influenza A virus, and
reassortant viruses bearing the ca and ts properties of the attenuated donor virus
were isolated.
Ideally, reassortant viruses produced by mating the A/Ann Arbor/6/60 ca donor
and a new epidemic influenza A virus should receive all their nonsurface viral pro-
tein genes from the ca donor and their surface glycoprotein genes from the new
variant. Maassab and his associates have produced ca reassortants with this gene
constellation by mating the A/Ann Arbor/6/60 ca donor and wild-type virus at
25°C, a temperature restrictive for replication of wild-type virus. Sixty-six percent
of ca reassortants produced in this manner have the desired gene constellation [7].
Clinical studies have shown that the six transferable genes present in the A/Ann
Arbor/6/60 donor virus canrender epidemicinfluenza Aviruses attenuatedfor fully
susceptible individuals. During replication in susceptible individuals, most of the ca
reassortant viruses were stable genetically. Those reassortant viruses that possessed
all six transferable A/Ann Arbor/6/60 genes retained the ts and ca phenotypes.
However, instability of the ca phenotype was observed with two reassortants that
received only five of the six transferable A/Ann Arbor/6/60 genes [6]. These find-
ings suggest that the potential for genetic instability exists. What is not clear, how-
ever, is the effect of such genetic change on attenuation. Perhaps other silent muta-
tions that have been introduced into genes of the ca donor will provide a safety net
that prevents reversion to virulence.
It is clear that one of the most urgent needs in immunoprophylaxis is the develop-
ment of satisfactorily attenuated mutants that are completely stable with respect to
phenotype. Restriction of growth of an attenuated mutant in vivo exerts positive
selection for new mutations that allow the virus to grow better and to escape the
limitations imposed by its original mutations. We need stable mutants that are
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during replication in completely susceptible individuals.
It may be possible to produce stable attenuated reassortant influenza viruses by
using an avian influenza A virus that is restricted in primate cells as the donor of at-
tenuating genes [6]. In this situation, restriction would be effected by naturally oc-
curring avian influenza virus genes rather than by mutant genes selected by limited
passage of human virus in an unnatural host. In studies performed by Murphy in
collaboration with Hinshaw, Webster, and London, potential avian influenza A
donor viruses were evaluated for evidence of restriction of growth in squirrel
monkeys. Two of ten influenza A viruses recovered from asymptomatic birds were
clearly restricted in their replication in the lower respiratory tract of the squirrel
monkey. These two viruses appeared to be of avian origin since they were strongly
enterotropic in ducks, a property not exhibited by human influenza A viruses.
Reassortants produced by mating a restricted avian virus with a virulent human
influenza A virus are currently under study by Murphy in an attempt to identify the
avian influenza gene or genes responsible for restriction of growth in primate cells,
as well as possible incompatible human-avian gene constellations that might also
restrict growth. Once the restricting avian genes and incompatible human-avian gene
constellations are identified, it should be possible to construct an appropriate donor
virus by genetic reassortment. Studies in progress indicate the feasibility of this ap-
proach. It appears that avian surface antigen genes are not required for restriction of
human-avian influenza virus reassortants. On the other hand, the other six trans-
ferable avian genes can confer the desired level of attenuation on human-avian
reassortants. Significantly, infection of monkeys with a restricted reassortant of this
sort induces almost complete resistance to challenge with a virulent human H3N2 in-
fluenza A virus.
Many of the influenza genes that have evolved over a long period of time in birds
differ significantly from the corresponding genes of human influenza viruses when
studied by nucleic acid hybridization [8]. Because of these marked differences, it is
likely that the avian genes will retain their attenuated characteristics after limited
replication in man, and thereby prove to be stable phenotypically.
Deletion Mutants: Negative-Strand RNA Viruses
Another approach to the construction of stable mutants involves deletion muta-
tions that should be stable because they are not subject to reversion, and itisunlikely
that they would be easily suppressed by a new mutation at another site on the viral
genome. For these reasons we have initiated attempts to produce stable deletion
mutations that will render a virus sufficiently defective so that it becomes attenu-
ated, but not so defective that it loses viability. This type ofgenetic surgery can only
be performed on DNA. Hence those viral genomes that are composed of RNA must
be transcribed into DNA and then manipulated in this form. This presents us with
the difficult problem of transcribing mutant DNA into an RNA form that can be
transferred back into an infectious virus.
Before discussing strategy for producing stable deletion mutants for use in im-
munoprophylaxis, it should be noted that viable deletion mutants of several DNA
animal viruses, including adenoviruses and papovaviruses, have been prepared, and
some of these mutants exhibit a reduced capacity for viral replication in vitro and in
vivo [9-11]. This is of interest because reduced replicative capacity is synonymous
with attenuation.
The general plan for construction of deletion mutants of negative-strand RNA
364 ROBERT M. CHANOCKNEW LIVE VIRAL VACCINES
viruses was developed initially by Lai, and Markoff and Sveda for influenza A virus
[12,131. In the first phase of this plan, individual virus RNA gene segments were
cloned using an Escherichia coli K12 plasmid system. Putative full-length influenza
virus DNA segments were obtained corresponding to genes coding for the NS pro-
teins (gene 8), the M proteins (gene 7), the neuraminidase (gene 6), the nucleoprotein
(gene 5), and the hemagglutinin (gene 4). Sequence analysis of the terminal nucleo-
tides of most cloned influenza DNA segments indicated that both ends of virion
RNA were fully represented. This suggested that these cloned DNAs were complete
and contained all the information present in the viral RNA segments from which
they were derived. This was verified for the NA, M, and NS genes by sequencing the
entire cloned DNA. Thus, RNA transcribed from such cloned DNA should have all
the control signals for viral gene replication and expression in eukaryotic cells.
In the second phase of the plan, full-length cloned influenza DNA was used to
produce influenza RNA in eukaryotic cells [13]. A late region deletion mutant of
SV40 was used for construction of influenza DNA-SV40 hybrid molecules. The in-
fluenza DNA was inserted into the late region of the SV40 genome previously oc-
cupied by the deleted sequences that code for SV40 capsid proteins. This type of
hybrid DNA molecule was propagated in eukaryotic cells that were coinfected with
an early ts mutant of SV40. When cell cultures were incubated at a restrictive tem-
perature, the hybrid influenza DNA-SV40 molecule supplied the function defective
in the SV40 early ts mutant and vice versa, thereby permitting both SV40 molecules
to replicate. Replication of influenza DNA-SV40 hybrid molecules in eukaryotic
cells resulted in transcription ofinfluenza messenger RNA and expression ofthe ap-
propriate functional influenza protein [131. Currently Lai, Markoff, Sveda, and Lin
are investigating the possibility that cloned influenza DNA in SV40 may be
transcribed into negative-strand influenza viral RNA. If negative-strand RNA is
produced, it may be possible to rescue it from cells by coinfecting with an influenza
virus and selecting for reassortant virus particles containing RNA coded for by the
cloned DNA. In this manner, stable, site-specific mutations, such as deletions, in-
troduced into the cloned DNA by enzyme surgery, might betransferred back into in-
fluenza virus.
Deletion Mutants: Positive-Strand RNA Viruses
Recently, a complete cloned DNA copy of the positive-strand RNA genome of
poliovirus was constructed by joining three partial clones of this virus [141. Signifi-
cantly, the complete cloned DNA was infectious for simian and human cells in cul-
ture. This important observation by Racaniello and Baltimore suggests that the cell
recognizes the appropriate control signals in the cloned poliovirus DNAandemploys
those signals to transcribe complete (+) strands of poliovirus RNA that initiate the
normal cycle of infection. Construction of deletion mutants of poliovirus and other
picornaviruses, as well as other (+) RNA viruses such as togaviruses, should be
relatively simple because altered cloned DNA could be transferred directly into in-
fectious virus by transfection of cells in culture. In this manner viable deletion
mutants could be identified and evaluated subsequently for attenuation and im-
munogenicity.
Double-Stranded RNA Viruses
The control ofrotaviral infection in infancy and early childhood represents an im-
portant public health challenge since 50 percent or more of severe pediatric diar-
rheal disease in most parts ofthe world is caused by the rotaviruses [15]. It should be
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noted that diarrheal disease is the leading cause of mortality in infants and young
children in developing countries. Efforts at immunoprophylaxis have been
hampered by the fastidious nature of the human rotaviruses. Until recently, these
viruses could not be grown serially to high titer in tissue culture. Fortunately, this
obstacle was overcome during the past two years.
The first success in cultivation of human rotavirus was reported by Wyatt and his
associates in our laboratory [16]. He identified a tissue culture-adapted mutant of
the Wa strain oftype 2 rotavirus that emerged during serial passage ofthis virus in a
permissive animal host, the gnotobiotic piglet. The tissue culture-adapted mutant
grew to high titer and was shown to be of human origin by polyacrylamide gel
analysis of its RNA and by cross-neutralization studies.
Similar efforts to select a culture-adapted mutant oftype 1 human rotavirus failed
since this virus could not be passaged in piglets. For this reason, Greenberg and his
associates developed another strategy which took into account the segmented viral
genome of the rotaviruses that belong to the family Reoviridae [17]. He was suc-
cessful in rescuing noncultivatable type 1 human rotavirus by gene reassortment dur-
ing coinfection with a cultivatable, temperature-sensitive (ts) mutant of bovine
rotavirus [17].
Recently, refinements in tissue culture technique have made it possible to recover
strains of each of the three human rotavirus serotypes directly in cell culture [18].
The scene is now set to evaluate different strains ofhuman rotavirus for attenuation
and immunogenicity in man. Manipulation ofthese strains to produce cold-adapted
mutants may yield the desired attenuated viruses. Also, evaluation of a variety ofin-
terspecies reassortant viruses in experimental animals and in humans may shed light
on the genetic determinants of virulence, allowing us to identify certain mixed con-
stellations of animal and human rotavirus genes that render viral reassortants at-
tenuated for man and thus suitable for use in a live attenuated rotavirus vaccine. It
should also be noted that antigenic relationships between animal and human rota-
viruses may allow us to use the former in prophylaxis of human disease. Several
years ago we showed that prior infection of calves with a bovine rotavirus protected
these animals against experimental challenge with type 2 human rotavirus [19].
Double-Stranded DNA Viruses
Previously, it was shown by our group that oral administration of live type 4
adenovirus in an enteric-coated capsule produced a silent infection in the lower in-
testinal tract that induced effective immunity to type 4 virus [20]. This type ofsilent,
selective, enteric adenovirus infection served as the basis for the development of a
type4, type 7 adenovirus vaccine that has effectively controlled epidemic adenovirus
disease in military recruits in the U.S.A. during the past 12 years. Concern for the
oncogenic potential of adenoviruses has prevented extension of this method of im-
munization to other adenovirus serotypes, especially those important in pediatric
respiratory tract disease. Although intensive efforts to link adenoviruses to human
cancer have failed to establish an association, concern for possible oncogenicity
lingers on. Perhaps DNA surgery can be combined with enteric vaccination to yield
an effective vaccine that will gain acceptance for use in children.
The genes of type 5 adenovirus responsible for cell transformation reside in
the left-hand 8 percent ofthe viral genome. Using a restriction enzyme that cuts at a
site 4 percent from the left-hand end of the viral genome, Jones and Shenk selected
spontaneous deletion mutants lacking this site and often flanking sequences as well
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[10]. Some of these deletion mutants exhibited the following properties desirable for
a vaccine virus: (1) viability, (2) restriction of replicative capacity in human cells,
and (3) inability to transform cells in culture. These observations suggest that it
should be possible to derive other mutants with a deletion in the transformation
region that renders the affected viruses transformation-defective and restricted in
their growth in human cells. The degree of growth restriction represents a critical
property because the desired mutants must still be sufficiently competent to infect
enough cells in vivo to stimulate immunity.
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